|
CFO of IDM Pharma plans to step down
(Science Letter Via Thomson Dialog NewsEdge)
IDM Pharma, Inc., (IDMI) announced that Robert De Vaere will resign effective March 31, 2006, from his position as VP, chief financial officer and secretary.
De Vaere served as VP, finance and administration and chief financial officer of Epimmune, Inc., and had assumed the role of CFO of IDM Pharma, Inc., following the business combination of Epimmune and IDM S.A. in August 2005.
Until the effective date of his resignation, De Vaere will continue to work as a full-time employee at IDM to assist in the transition of his responsibilities.
Jean-Loup Romet-Lemonne, MD, chairman and CEO of IDM said, "Bob was not only a key member of the Epimmune management team for over 5 years, he also played an instrumental role in integrating the businesses, systems and processes of Epimmune and IDM, S.A. We believe we are well positioned to capitalize on those efforts and we thank Bob for his outstanding contributions and integrity and wish him well in his future career endeavors."
IDM is currently developing two types of products: the first is designed to destroy cancer cells by activating innate immunity, and the second to prevent tumor recurrence by triggering a specific adaptive immune response.
IDM Pharma currently has 5 products in clinical development. The most advanced product, Junovan, has completed a phase III clinical trial in osteosarcoma. Three products are in phase II clinical trials in bladder cancer, melanoma and non-small cell lung cancer, and one is in phase I in colorectal cancer.
This article was prepared by Science Letter editors from staff and other reports. Copyright 2006, Science Letter via NewsRx.com.
[ Back To TMCnet.com's Homepage ]
|
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 16-18, 2008. Los Angeles, California.
